| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/18/2023 | 588.26% | B of A Securities | → $17 | Initiates Coverage On | → Buy |
| 08/07/2023 | 709.72% | Morgan Stanley | $20 → $20 | Reiterates | Overweight → Overweight |
| 04/26/2023 | 669.23% | SVB Securities | $16 → $19 | Maintains | Outperform |
| 01/27/2023 | 709.72% | Morgan Stanley | $27 → $20 | Maintains | Overweight |
| 01/23/2023 | 669.23% | SVB Leerink | $25 → $19 | Maintains | Outperform |
| 11/07/2022 | 912.15% | SVB Leerink | $24 → $25 | Maintains | Outperform |
| 09/09/2022 | 993.12% | Morgan Stanley | $32 → $27 | Maintains | Overweight |
| 07/28/2022 | 831.17% | SVB Leerink | $30 → $23 | Maintains | Outperform |
| 05/19/2022 | 1276.52% | Piper Sandler | $55 → $34 | Maintains | Overweight |
| 02/10/2022 | 1114.57% | SVB Leerink | $32 → $30 | Maintains | Outperform |
| 01/18/2022 | 1721.86% | Morgan Stanley | $48 → $45 | Maintains | Overweight |
| 12/17/2021 | 1195.55% | SVB Leerink | $37 → $32 | Maintains | Outperform |
| 11/08/2021 | 1397.98% | SVB Leerink | $41 → $37 | Maintains | Outperform |
| 10/12/2021 | 1843.32% | Morgan Stanley | $47 → $48 | Maintains | Overweight |
| 09/29/2021 | 9009.31% | Morgan Stanley | $175 → $225 | Maintains | Overweight |
| 08/18/2021 | 1802.83% | Morgan Stanley | $50 → $47 | Maintains | Overweight |
| 05/06/2021 | 1600.4% | SVB Leerink | $41 → $42 | Maintains | Outperform |
| 04/19/2021 | 1924.29% | Morgan Stanley | $49 → $50 | Maintains | Overweight |
| 08/24/2020 | 1924.29% | JP Morgan | → $50 | Initiates Coverage On | → Overweight |
| 08/24/2020 | 1883.81% | Morgan Stanley | → $49 | Initiates Coverage On | → Overweight |
| 08/24/2020 | 1559.92% | SVB Leerink | → $41 | Initiates Coverage On | → Outperform |
What is the target price for AlloVir (ALVR)?
The latest price target for AlloVir (NASDAQ: ALVR) was reported by B of A Securities on August 18, 2023. The analyst firm set a price target for $17.00 expecting ALVR to rise to within 12 months (a possible 588.26% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AlloVir (ALVR)?
The latest analyst rating for AlloVir (NASDAQ: ALVR) was provided by B of A Securities, and AlloVir initiated their buy rating.
When is the next analyst rating going to be posted or updated for AlloVir (ALVR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AlloVir, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AlloVir was filed on August 18, 2023 so you should expect the next rating to be made available sometime around August 18, 2024.
Is the Analyst Rating AlloVir (ALVR) correct?
While ratings are subjective and will change, the latest AlloVir (ALVR) rating was a initiated with a price target of $0.00 to $17.00. The current price AlloVir (ALVR) is trading at is $2.47, which is within the analyst's predicted range.